GURU.Markets stock price, segment price, and overall market index valuation
The company's share price OCX
Omega Therapeutics, a company developing epigenetic drugs, is a venture capital bet on its scientific platform. Its price reflects not current revenues, but rather investors' faith in the potential of gene expression control technology and their dependence on news about clinical trials.
Share prices of companies in the market segment - Cancer analysis
OncoCyte Corporation is a molecular diagnostics company developing tests for cancer detection and treatment. We've categorized it as "Cancer Analysis." The chart below shows how the market values companies at the forefront of cancer diagnostics.
Broad Market Index - GURU.Markets
OncoCyte Corporation is a molecular diagnostics company developing tests for cancer detection and treatment. We've categorized it as "Cancer Analysis." The chart below shows how the market values companies at the forefront of cancer diagnostics.
Change in the price of a company, segment, and market as a whole per day
OCX - Daily change in the company's share price OCX
OncoCyte Corporation's daily stock price reflects volatility in the cancer diagnostics sector. The indicator demonstrates sensitivity to news about the introduction of its cancer monitoring and diagnostic tests.
Daily change in the price of a set of shares in a market segment - Cancer analysis
OncoCyte Corporation develops and markets diagnostic tests for cancer detection. The oncodiagnostics sector is extremely sensitive to clinical trial results and the commercial success of these tests. The chart below illustrates the volatility in this niche, reflecting both high expectations and risks.
Daily change in the price of a broad market stock, index - GURU.Markets
OncoCyte specializes in cancer diagnostics. The company's shares react to news of its tests' acceptance by the medical community. This specific volatility, driven by medical innovation, feeds into the overall market movement.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization OCX
OncoCyte Corporation's year-over-year performance tells the story of its struggle to commercialize its cancer diagnostic tests. Its market cap change over the past 12 months reflects its success (or failure) in generating revenue from its tests, as well as its ongoing need for funding, a key challenge for survival in this competitive field.
Annual dynamics of market capitalization of the market segment - Cancer analysis
OncoCyte is a cancer diagnostics company focused on commercializing its innovative tests. This chart shows how its struggle for market share, reimbursement system dependence, and competition are impacting its volatile performance in the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
OncoCyte, a cancer diagnostics company, develops tests for the detection and monitoring of the disease. Its year-over-year market capitalization reflects the progress of its tests' commercialization and their acceptance by the medical community.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization OCX
OncoCyte is a molecular diagnostics company. Its monthly performance reflects progress in the commercialization of its oncology tests. News about lab partnerships and data confirming the accuracy of its tests are key.
Monthly dynamics of market capitalization of the market segment - Cancer analysis
OncoCyte is a molecular diagnostics company that develops and markets cancer detection tests. Their goal is early and accurate diagnosis that can save lives. The chart below shows the overall dynamics of the cancer testing sector, where liquid biopsy technologies and other innovations are changing approaches to oncology.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Oncology diagnostics stocks are betting on the future of personalized medicine. The chart below shows investors' overall risk appetite. Is OncoCyte Corporation moving in sync with the market's growth, or are its scientific advances creating their own trend?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization OCX
OncoCyte, a cancer diagnostics company, shares reflect progress in the field on a weekly basis. Price movements reflect the commercial success of its tests and data confirming their accuracy in detecting and monitoring cancer.
Weekly dynamics of market capitalization of the market segment - Cancer analysis
OncoCyte Corporation specializes in the development and commercialization of cancer diagnostic tests. This chart compares its weekly performance with the sector and helps understand how the market views its products amid rapid technological change and intense competition in the liquid biopsy field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
OncoCyte is a medical diagnostics company specializing in cancer. Shares of such companies may be less dependent on general economic cycles. This chart will help us understand whether OncoCyte shares are living in a world of clinical trials, or whether the overall market environment still influences their stock price.
Market capitalization of the company, segment and market as a whole
OCX - Market capitalization of the company OCX
OncoCyte's market capitalization chart tells the story of a company developing diagnostic tests for early cancer detection. Its decline on the chart reflects its long and arduous journey from scientific development to commercialization and insurance reimbursement. Its dynamics reflect the market's assessment of its chances of success in this complex field.
OCX - Share of the company's market capitalization OCX within the market segment - Cancer analysis
OncoCyte develops and markets cancer diagnostic tests. The company's share of its segment's market capitalization reflects the commercial potential of its products. The chart below illustrates how the market evaluates its technologies and its ability to compete in the rapidly growing oncology diagnostics market.
Market capitalization of the market segment - Cancer analysis
OncoCyte is a company developing and commercializing diagnostic tests for cancer detection. The graph below shows the market capitalization of this innovative sector. Its growth reflects the importance of early and accurate diagnosis for successful cancer treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
OncoCyte is a company developing diagnostic tests for the early detection of cancer. Its market cap reflects the bet that liquid biopsy and other non-invasive methods will transform oncology. Its performance on the overall chart reflects how the market views a future where cancer can be detected through blood tests.
Book value capitalization of the company, segment and market as a whole
OCX - Book value capitalization of the company OCX
OncoCyte's foundation is its laboratories, capital, and patents for diagnostic tests for cancer detection and monitoring. This is real, science-intensive capital for liquid biopsy and other advanced diagnostic methods. How has this innovative, yet troubled, asset evolved? The chart below shows its history.
OCX - Share of the company's book capitalization OCX within the market segment - Cancer analysis
OncoCyte specializes in developing diagnostic tests for oncology, which requires certified laboratories. The chart shows the share of these tangible assets, reflecting the physical foundation on which its early cancer detection business is built.
Market segment balance sheet capitalization - Cancer analysis
OncoCyte, a cancer diagnostics company, has a capital-intensive business. This requires the ownership of certified laboratories. The BCap_Seg chart for the medical equipment sector shows that leadership in diagnostics requires a significant financial base.
Book value of all companies included in the broad market index - GURU.Markets
OncoCyte's assets include its diagnostic tests and cancer laboratories. The company's book value reflects its intellectual property, technologies, and laboratory equipment. The chart below allows you to estimate the material weight of this player in the molecular diagnostics market for cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - OCX
OncoCyte Corporation specializes in cancer diagnostics. Its book value is derived from its laboratories and the tests it develops. Its market valuation reflects the belief in the accuracy and demand for its diagnostic products in medical practice. The chart shows how the market views its competitive position in the oncology diagnostics market.
Market to book capitalization ratio in a market segment - Cancer analysis
OncoCyte Corporation develops and commercializes innovative cancer diagnostic tests. Its market valuation in the chart is based on the potential of its technologies to improve early detection and treatment of cancer, a huge market.
Market to book capitalization ratio for the market as a whole
OncoCyte Corporation, a cancer diagnostics company, creates value through its tests and technologies. Its market valuation reflects the potential of its products, not the cost of its laboratories. This chart shows the market premium the market is willing to pay for innovations in medical diagnostics compared to traditional sectors.
Debts of the company, segment and market as a whole
OCX - Company debts OCX
OncoCyte Corporation, a molecular diagnostics company, is using capital to develop and commercialize its cancer detection tests. This chart shows how the company is funding its expensive research and validation efforts, seeking to carve out a niche in the rapidly growing but competitive diagnostic testing market.
Market segment debts - Cancer analysis
OncoCyte is a molecular diagnostics company focused on oncology. Developing and commercializing diagnostic tests is an expensive process. This chart shows how the company funds its research and development efforts to bring its tests to market, and how much it relies on external capital to sustain its operations until it reaches profitability.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio OCX
OncoCyte Corporation develops and commercializes diagnostic tests for cancer detection. This chart shows the company's use of debt to fund its research, development, and marketing efforts to introduce its tests into clinical practice. It helps assess its financial stability.
Market segment debt to market segment book capitalization - Cancer analysis
OncoCyte Corporation develops and commercializes diagnostic tests for the detection and treatment of cancer. Early detection is a key trend in oncology. The chart shows how the biotech sector uses debt to fund R&D, providing context for assessing how OncoCyte finances its capital-intensive developments.
Debt to book value of all companies in the market
OncoCyte Corporation develops diagnostic tests for cancer detection, which requires investment in research, clinical validation, and commercialization. This chart shows the overall debt burden in the market. It allows one to assess how the diagnostics company manages its capital on its path to profitability and widespread adoption of its tests.
P/E of the company, segment and market as a whole
P/E - OCX
OncoCyte Corporation develops and markets diagnostic tests for cancer detection. This chart shows the market sentiment for its liquid biopsy technology. The trend reflects the belief that noninvasive blood-based tests will become a key tool in early cancer detection and monitoring.
P/E of the market segment - Cancer analysis
This chart for companies in the medical diagnostics sector serves as a benchmark for OncoCyte. It reflects general expectations for the growth of personalized medicine. Comparisons with it help understand how the market values OncoCyte's cancer diagnostic tests and whether they have the potential to carve out a niche in this competitive market.
P/E of the market as a whole
OncoCyte is a company developing and commercializing diagnostic tests for cancer detection. Its valuation is a bet on its technology platform. It is not tied to the general economic cycles shown by this chart, but depends on its ability to demonstrate the accuracy of its tests and achieve widespread clinical adoption.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company OCX
For OncoCyte Corporation, a company developing diagnostic tests for cancer detection, this chart illustrates market expectations for future sales of its tests. It reflects forecasts for their clinical adoption and the company's ability to prove their effectiveness to physicians and insurance companies.
%20P%2FE%20OCX&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-OCX&v=1772524535070 "Chart of the company's future (projected) P/E OCX")
Future (projected) P/E of the market segment - Cancer analysis
OncoCyte is a molecular diagnostics company developing and commercializing tests for cancer detection and treatment. Its products help physicians make decisions throughout the patient journey. The chart shows forecasts for the oncology sector. This helps assess the market's confidence in the clinical benefit and commercial potential of OncoCyte's diagnostic tests.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-analysis&v=1772524535151 "Future (projected) P/E graph of the market segment - Cancer analysis")
Future (projected) P/E of the market as a whole
OncoCyte Corporation develops and commercializes diagnostic tests for cancer detection. This is an important area of personalized medicine. This market sentiment chart influences how investors evaluate companies whose technologies could change approaches to cancer diagnosis and treatment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772524535218 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit OCX
OncoCyte Corporation is a molecular diagnostics company developing tests for early-stage cancer detection. Profits depend on the commercialization of its tests. This graph shows the complex path from scientific development to the creation of a product accepted by doctors and covered by insurance companies.
Profit of companies in the market segment - Cancer analysis
OncoCyte Corporation is a diagnostics company focused on the development and commercialization of cancer detection tests. This chart, reflecting profitability in the cancer testing sector, demonstrates the importance of early detection. Their tests are designed to help doctors make more informed treatment decisions, improving patient outcomes.
Overall market profit
OncoCyte Corporation is a company specializing in the development and commercialization of diagnostic tests for early cancer detection. Its goal is to make diagnostics less invasive and more accurate. The company's growth depends on the acceptance of its tests by the medical community. The overall economic stability, visible in this chart, facilitates the implementation of innovations in medicine.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company OCX
OncoCyte Corporation focuses on the development and commercialization of diagnostic tests for early cancer detection. Its tests help doctors make treatment decisions. This chart reflects analysts' forecasts for sales volumes of these tests and their clinical adoption, which is important for the development of personalized oncology.
%20profit%20of%20the%20company%20OCX&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-OCX&v=1772524535401 "Graph of future (projected) profit of the company OCX")
Future (predicted) profit of companies in the market segment - Cancer analysis
OncoCyte Corporation is a molecular diagnostics company developing and commercializing cancer detection tests. Its goal is to provide doctors with tools for early diagnosis and treatment decision-making. Growth depends on the adoption of its tests. This chart for the medical diagnostics sector reflects expectations for the growth of personalized medicine and the demand for innovative tests.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-analysis&v=1772524535517 "Graph of future (predicted) profits of companies in a market segment - Cancer analysis")
Future (predicted) profit of the market as a whole
OncoCyte Corporation specializes in cancer diagnostics. Demand for its tests depends on innovations in oncology. The overall profit forecast, reflected in this chart, influences healthcare budgets and the willingness to pay for advanced diagnostic tools that can improve treatment outcomes.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772524535665 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - OCX
OncoCyte Corporation specializes in the development and commercialization of diagnostic tests for cancer detection. The chart shows how investors estimate its revenue from test sales. It reflects its belief in the growth of the early cancer detection market and the value of its products in improving patient outcomes.
P/S market segment - Cancer analysis
OncoCyte Corporation develops and commercializes non-invasive tests for early-stage cancer diagnosis. The company's revenue depends on the clinical adoption of its diagnostic products. This chart reflects the average valuation in the sector, providing insight into how investors view the potential of OncoCyte's liquid biopsy technology.
P/S of the market as a whole
OncoCyte is a molecular diagnostics company that develops and commercializes tests for cancer detection and treatment. This chart, showing average market revenue estimates, helps understand the premium investors are willing to pay for technologies that can improve early cancer detection and personalize treatment, a key trend in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company OCX
OncoCyte is a molecular diagnostics company specializing in the development of cancer detection tests. Its goal is to provide physicians with tools for early and accurate diagnosis. This chart reflects investor expectations for the future clinical adoption and commercial success of its tests.
%20P%2FS%20OCX&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-OCX&v=1772524536118 "The graph of the company's future (projected) P/S OCX")
Future (projected) P/S of the market segment - Cancer analysis
OncoCyte Corporation is a company developing and commercializing diagnostic tests for cancer detection. Its tests are aimed at the early detection and monitoring of oncological diseases. This chart shows the average estimated future sales in the medical diagnostics sector. It helps understand how the market perceives OncoCyte's potential in the fight against cancer.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-analysis&v=1772524536251 "Future (projected) P/S market segment graph - Cancer analysis")
Future (projected) P/S of the market as a whole
OncoCyte Corporation develops and commercializes liquid biopsy-based diagnostic tests for early-stage cancer detection. This chart illustrates overall market expectations. OncoCyte's technologies are at the forefront of cancer diagnostics. Their success could fundamentally change approaches to cancer screening and treatment, fueling investor optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772524536307 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales OCX
This chart illustrates the sales of OncoCyte Corporation, a company specializing in molecular cancer diagnostics. Revenue is generated from its tests, which help doctors make treatment decisions. The dynamics in this chart reflect the number of tests sold and their adoption in clinical practice.
Sales of companies in the market segment - Cancer analysis
OncoCyte Corporation specializes in the development and commercialization of diagnostic tests for early cancer detection. This chart reflects the growth of the oncology diagnostics market. The company's blood and tissue analysis products have the potential to revolutionize approaches to screening and treatment, representing one of the most promising areas in medicine.
Overall market sales
OncoCyte Corporation develops and commercializes diagnostic tests for cancer detection. Demand for its products is growing with the advancement of preventive medicine. The overall economic situation, reflected in this chart, influences healthcare system budgets and their willingness to implement new early detection methods.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company OCX
OncoCyte is a molecular diagnostics company developing tests for early-stage cancer detection. Future revenue depends on the clinical adoption of its tests and insurance coverage. The chart shows the forecast for the oncology diagnostics market growth.
%20sales%20of%20the%20company%20OCX&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-OCX&v=1772524536508 "Schedule of future (projected) sales of the company OCX")
Future (projected) sales of companies in the market segment - Cancer analysis
OncoCyte Corporation is a molecular diagnostics company developing and commercializing tests for cancer detection and treatment. Its products help doctors detect cancer at early stages and tailor treatment. This chart shows the forecast for the entire cancer testing market, where early detection, like OncoCyte's, is crucial.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-analysis&v=1772524536558 "Schedule of future (projected) sales of companies in the market segment - Cancer analysis")
Future (projected) sales of the market as a whole
OncoCyte is a molecular diagnostics company specializing in tests for cancer detection and treatment. Demand for their products is driven by the advancement of personalized medicine. This trend, reflecting overall healthcare costs, influences the willingness of insurers and hospitals to cover advanced diagnostic tests.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772524536588 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality OCX
OncoCyte specializes in the development and commercialization of diagnostic tests for early cancer detection. The company's profitability depends on the clinical adoption of its tests and reimbursement from insurance companies. This graph illustrates the complex path from scientific development to the creation of a commercially successful diagnostic product.
Market segment marginality - Cancer analysis
OncoCyte is a molecular diagnostics company developing and commercializing tests for early cancer detection. Profitability depends on the acceptance of their tests by the medical community, sales volume, and insurance reimbursement. This chart shows the financial results of their operations at the forefront of the fight against cancer.
Market marginality as a whole
OncoCyte Corporation is a molecular cancer diagnostics company. They develop tests that aid in the early detection and treatment of cancer. This overall profitability curve is not important to them. Their growth is determined by the clinical acceptance of their tests, diagnostic innovations, and insurance reimbursement for their services.
Employees in the company, segment and market as a whole
Number of employees in the company OCX
OncoCyte is a cancer-focused diagnostics company. Its team consists of scientists and laboratory technicians who develop and perform tests. This chart reflects the scale of its laboratory operations and investment in research to create new diagnostic products.
Share of the company's employees OCX within the market segment - Cancer analysis
OncoCyte Corporation focuses on the cancer diagnostics market, developing tests that help doctors make treatment decisions. This chart reflects the company's personnel footprint in the high-tech medical sector. It shows the size of its scientific and laboratory team working on the development and commercialization of innovative diagnostic solutions.
Number of employees in the market segment - Cancer analysis
OncoCyte Corporation is a molecular diagnostics company specializing in the development and commercialization of tests for the detection and treatment of cancer. This chart illustrates employment trends in the oncodiagnostics sector. The growth in the number of laboratory technicians and scientists reflects advances in the development of non-invasive tests that can aid in the early detection and monitoring of cancer.
Number of employees in the market as a whole
OncoCyte Corporation specializes in developing cancer diagnostic tests. Demand for its products depends on investments in healthcare and the introduction of new diagnostic methods. Overall economic growth, reflected in this chart, supports stable funding for medical institutions, which are OncoCyte's primary clients.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company OCX (OCX)
OncoCyte Corporation develops and commercializes diagnostic tests for cancer detection. This is the molecular diagnostics sector. The company's value lies in the accuracy of its tests, patents, and laboratory infrastructure. The chart shows how the market values this high-tech business. The high per-employee ratio reflects that the company's primary value is generated in its R&D lab, rather than through mass manual labor.
%20of%20the%20company%20OCX%20(OCX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-OCX-OCX&v=1772524537178 "Chart of market capitalization per employee (in thousands of dollars) of the company OCX (OCX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer analysis
OncoCyte Corporation develops and commercializes diagnostic tests for cancer detection. It is a high-tech company whose value lies in the accuracy and uniqueness of its tests. This chart shows how the market values its intellectual property and its potential to transform approaches to cancer diagnosis.
%20by%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-analysis&v=1772524537307 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer analysis")
Market capitalization per employee (in thousands of dollars) for the overall market
OncoCyte Corporation develops and markets diagnostic tests for cancer detection. The chart shows the market's assessment of the molecular diagnostics sector. It reflects how the market perceives the potential of their tests for early cancer detection and monitoring, one of the most important tasks in modern medicine.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772524537576 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company OCX (OCX)
OncoCyte is a molecular cancer diagnostics company. They develop and sell tests that help doctors make treatment decisions for conditions such as lung and kidney cancer. It's a research-intensive business. This chart shows their path to profitability: their profit per employee depends on the number of tests sold and the amount insurers are willing to pay for them.
%20Chart%20OCX%20(OCX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-OCX-OCX&v=1772524537641 "Company Profit Per Employee (in thousands of dollars) Chart OCX (OCX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer analysis
OncoCyte is a molecular cancer diagnostics company. They develop and commercialize tests that aid in the early detection and treatment of cancer. They are a laboratory business. This metric reflects the balance between test revenue and high R&D costs.
%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-analysis&v=1772524537717 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer analysis")
Profit per employee (in thousands of dollars) for the market as a whole
OncoCyte Corporation is a biotechnology company specializing in cancer diagnostic tests (liquid biopsy). This includes R&D and services. This chart shows how their tests (margin) are in demand in a highly competitive environment and how successfully they are commercialized, covering R&D costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772524537757 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee OCX (OCX)
OncoCyte is a molecular diagnostics company developing tests for early cancer detection. This chart demonstrates the commercial success of its diagnostic products. The growth in revenue per employee reflects the adoption of its tests in clinical practice and the increased volume of tests performed in its laboratories.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-OCX-OCX&v=1772524537816 "Sales chart per company employee OCX (OCX)")
Sales per employee in the market segment - Cancer analysis
OncoCyte specializes in "liquid biopsies"—blood tests for the early detection of cancers (such as lung and bladder cancers). This chart shows how productive their team is. It measures how much revenue each employee (lab technician, scientist, salesperson) generates from selling these innovative tests, compared to other diagnostic companies.
Sales per employee for the market as a whole
OncoCyte (OCX) is a molecular diagnostics company developing tests (primarily blood-based) for cancer detection and treatment. It's a research-intensive business. This chart shows how effectively the company monetizes its diagnostic services. Revenue is generated in its laboratories and sold through a network of medical representatives.
Short shares by company, segment and market as a whole
Shares shorted by company OCX (OCX)
OncoCyte Corporation develops and markets diagnostic tests for cancer detection. This chart shows bearish bets. Investors likely doubt that its tests will gain widespread acceptance among doctors and, more importantly, insurance coverage, which is essential for commercial success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-OCX-OCX&v=1772524538073 "Short Shares Chart for the Company OCX (OCX)")
Shares shorted by market segment - Cancer analysis
OncoCyte Corporation operates at the forefront of medical science, developing tests for early-stage cancer diagnosis. This segment is precision biotechnology. This indicator measures the total volume of short positions across the entire molecular diagnostics industry. It reveals the overall level of investor skepticism toward business models and technologies in this sector, which is important for understanding the context in which OncoCyte operates.
Shares shorted by the overall market
OncoCyte (OCX) is an R&D company developing cancer diagnostics. It's a speculative bet. When this market fear indicator rises, investors' risk appetite plummets. They sell off unprofitable stocks like OCX, whose fate depends on R&D and regulatory approval.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator OCX (OCX)
This chart for OncoCyte is a barometer of demand for oncodiagnostics. The company develops tests (liquid biopsy) for cancer monitoring and diagnosis. "Overbought" levels (above 70) arise from news of test validation or insurance coverage. Slow adoption by doctors and high cash burn lead to "oversold" levels (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-OCX-OCX&v=1772524538164 "RSI 14 indicator chart for the company's stock OCX (OCX)")
RSI 14 Market Segment - Cancer analysis
OncoCyte (OCX) is a "liquid biopsy" for cancer. The company develops molecular tests (blood or urine tests) that help detect and treat cancer at an early stage. This chart tracks the collective "pulse" of the entire Cancer Testing sector. It helps investors understand whether OCX's performance reflects their data or whether the entire industry is overheated or oversold.
RSI 14 for the overall market
For OncoCyte, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OCX (OCX)
OncoCyte (OCX) is a molecular diagnostics company developing tests (including liquid biopsy) for early cancer detection. This chart shows the average 12-month forecast. It reflects analyst expectations for the commercialization of these tests, their clinical adoption, and insurance coverage (reimbursement).
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OCX-OCX&v=1772524538633 "A chart showing analyst consensus forecasts for the expected stock price. OCX (OCX)")
The difference between the consensus estimate and the actual stock price OCX (OCX)
OncoCyte (OCX) is a "liquid biopsy." The diagnostics company develops blood tests (DetermaIO) to predict the effectiveness of cancer immunotherapy. This chart shows how far the current share price differs from its "fair" value. It reflects analysts' faith in their diagnostic R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OCX-OCX&v=1772524538727 "A chart showing the difference between the consensus forecast and the actual stock price. OCX (OCX)")
Analyst consensus forecast for stock prices by market segment - Cancer analysis
OncoCyte is a "liquid biopsy" company. It develops diagnostic tests (blood, urine) for the early detection of cancer (lung, kidney). This chart reflects analysts' overall expectations for the *entire* cancer testing sector. It shows whether experts believe in a breakthrough in "non-invasive" tests or consider R&D too expensive.
Analysts' consensus forecast for the overall market share price
OncoCyte (OCX) is a company that "sees" cancer in the blood. They are developing "liquid" biopsies—diagnostic tests designed to detect cancer at an early stage. This is a bet on diagnostic R&D. This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough, but extremely risky, R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index OCX
OncoCyte is a cancer diagnostician. Their specialty is diagnostic tests (including liquid biopsy) for the early detection and monitoring of cancer (primarily lung and kidney). This chart summarizes their implementation history. It reflects their (slow) path to commercialization and their (difficult) struggle for reimbursement from insurance companies.
AKIMA Market Segment Index - Cancer analysis
OncoCyte (OCX) is a cancer analysis company. They develop liquid biopsies—diagnostic tests (using blood) that help doctors detect cancer and choose the right treatment. This chart compares their composite index to the sector, showing how their diagnostic platform compares to the competition.
The AKIM Index for the overall market
OncoCyte is a diagnostics company developing tests for transplantation (GraftAssure) and oncology. This chart, reflecting the market average, provides context. It helps assess how OncoCyte, as it restructures its business, compares to overall macroeconomic trends in diagnostics.
